COMMENTARY: Perioperative use of atoravasatin reduced cardiovascular events in patients having vascular surgery

Devereaux, P.J.
November 2004
ACP Journal Club;Nov/Dec2004, Vol. 141 Issue 3, p64
Academic Journal
iThe article presents a commentary on the study, which concluded that perioperative use of atoravasatin reduced cardiovascular events in patients having vascular surgery. Noncardiac surgery is associated with substantial cardiac morbidity and mortality. Despite this, few randomized controlled trials (RCTs) have evaluated interventions to prevent major cardiovascular events in patients having noncardiac surgery. The evidence that perioperative statin therapy reduces adverse cardiovascular outcomes is modest but encouraging.


Related Articles

  • ACP Journal Club: ACC/AHA guidelines determining statin eligibility better predicted CVD than ATP-III guidelines. Santos, Raul D. // Annals of Internal Medicine;11/17/2015, Vol. 163 Issue 10, pJC11 

    The article provides an answer to a question of how do the American College of Cardiology or American Heart Association (ACC/AHA) and Adult Treatment Panel III (ATP-III) guidelines for statin eligibility compare for predicting cardiovascular disease (CVD) in asymptomatic community-dwelling adults.

  • Pharmacology of statins: A brief overview. Patel, Bina // Nurse Prescribing;Sep2014, Vol. 12 Issue 9, p451 

    Statins have revolutionized the treatment of hypercholesterolaemia, a risk factor for cardiovascular disease (CVD). In the UK, statins are used for both the primary and secondary prevention of CVD, and the National Institute for Health and Care Excellence (2014) have recently published new...

  • High-dose statins of value for ACS, not so for CAD.  // PharmacoEconomics & Outcomes News;6/2/2007, Issue 529, p7 

    The article reports on the findings of researchers from the U.S. that high-dose statin therapy is cost effective for preventing cardiovascular events in patients with acute coronary syndromes (ACS), but may not be so for patients with coronary artery disease. Researchers found that high-dose...

  • Viewpoint: Personalizing Statin Therapy. Keidar, Shlomo; Gamliel-Lazarovich, Aviva // Rambam Maimonides Medical Journal;Apr2013, Vol. 4 Issue 2, p1 

    Cardiovascular disease (CVD), associated with vascular atherosclerosis, is the major cause of death in Western societies. Current risk estimation tools, such as Framingham Risk Score (FRS), based on evaluation of multiple standard risk factors, are limited in assessment of individual risk. The...

  • Dual therapy 'last resort' for CHD. Hensler, Paula // GP: General Practitioner;5/3/2004, p27 

    Statin and ezetimibe combination therapy should only be used as a last resort for high-risk coronary heart disease patients, according to general practitioners (GPs) with an interest in cardiology. However, GPs with an interest in cardiology say combination therapy with the new drug should be...

  • Should statins be used for primary prevention in the elderly?  // PharmacoEconomics & Outcomes News;May2015, Vol. 727 Issue 1, p29 

    The article discusses research being done on the cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease in older adults in the U.S. It references a study by M. C. Odden et al. published in the April 12, 2015 issue of the "Annals of Internal Medicine."...

  • The Role of Statins in Diabetes Treatment. Subedi, Bishnu H.; Tota-Maharaj, Rajesh; Silverman, Michael G.; Minder, Michael; Martin, Seth S.; Ashen, Dominique; Blumenthal, Roger S.; Blaha, Michael J. // Diabetes Spectrum;Summer2013, Vol. 26 Issue 3, p156 

    The article discusses the role of statins in the treatment of diabetics with or without cardiovascular disease (CVD). It states that the guidelines of the American Diabetes Association (ADA) and Joint American Heart Association recommend the use of statin in lifestyle changes of patients with...

  • Newer cholesterol guidelines better at identifying increased risk of CVD events.  // Clinical Advisor;Sep2015, Vol. 18 Issue 9, p27 

    No abstract available.

  • Meeting reporter.  // Patient Care for the Nurse Practitioner;Jan2006, Vol. 9 Issue 1, p8 

    The article offers news briefs related to medicine. Researchers at the American Heart Association's recent scientific sessions reported that, Cyclooxygenase-2 inhibitors or other NSAID use after a heart attack, especially in high dosages, increases the risk of death. Diet and low-dose...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics